Selective ALK-5 Inhibitors for Tumor Growth and Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for proliferative diseases such as cancer and fibrotic conditions associated with aberrant TGF-β signaling pathways are limited, and there is a need for additional compounds to effectively target activin receptor-like kinase 5 (ALK-5) to inhibit tumor growth and immune evasion.
Innovation Solution
Development of specific compounds, including those represented by Formulae (I), (II), and (III), which act as selective ALK-5 inhibitors, capable of regulating or inhibiting the TGFβ signaling pathway to treat fibrotic, inflammatory, and proliferative diseases by targeting ALK-5.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for proliferative diseases, then existing therapy options are available, but treatment effectiveness is limited due to lack of sufficient ALK-5 inhibition compounds
Solution Approach 1:
The patent segments the TGF-β receptor family into specific type I receptors (ALK-1 through ALK-7) and focuses inhibition specifically on ALK-5, allowing selective targeting of the pathological pathway while preserving other TGF-β signaling functions through different receptor types
Solution Approach 2:
The patent develops compounds with varying structural parameters (different R1, R2, R3, R4, R5 substituents in Formula I) to optimize ALK-5 inhibition potency and selectivity, creating a series of analogs with improved therapeutic properties
2Reliability
If TGF-β signaling is blocked to inhibit tumor growth, then proliferative disease progression is reduced, but immune evasion mechanisms may be affected
Solution Approach 1:
The patent uses small molecule ALK-5 inhibitors as intermediaries to block the aberrant TGF-β signaling pathway that promotes tumor growth and immune evasion, thereby restoring normal immune surveillance without completely abolishing TGF-β signaling functions
Solution Approach 2:
The patent applies ALK-5 inhibition preliminarily to prevent the establishment of immune evasion mechanisms by blocking TGF-β signaling before it can fully activate immunosuppressive pathways in the tumor microenvironment
Data Source
AI summary
Provided herein are compounds (e.g., compounds of Formulae (I), (II), (III) and (IV), or of Table 1 or Table 4), and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and kits comprising the same. The compounds provided herein are activin receptor-like kinase (e.g., ALK-5) inhibitors and are, therefore, useful, for example, for treating and/or preventing diseases (e.g., proliferative diseases, such as cancer) in a subject, inhibiting tumor growth in a subject, or inhibiting the activity of an activin receptor-like kinase (e.g., ALK-5) in vitro or in vivo. Also provided herein are methods and synthetic intermediates useful in the preparation of compounds described herein.